TopoTarget A/S
Symbion
Fruebjergvej 3
DK-2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

Copenhagen, Denmark - February 23, 2010 - TopoTarget A/S (NASDAQ OMX: TOPO.CO)
announced today that Francois Martelet, MD, takes up the position of CEO of
TopoTarget in order to add the necessary late-stage clinical development and
marketing expertise to ensure a successful development and commercialisation of
belinostat, TopoTarget's lead anticancer drug.

"I am delighted that Francois Martelet has accepted the role of CEO of
TopoTarget. Francois is extremely well placed to take TopoTarget successfully
through the coming development, regulatory process and commercialisation phase
of belinostat. He brings a comprehensive experience within international pharma
and the oncology field, and in-depth knowledge of the HDACi drug class. His
hands-on experience from late-stage clinical development and market
introductions of cancer drugs will be a valuable contribution to TopoTarget,"
said Dr. Håkan Åström, chairman of TopoTarget. "Furthermore, I wish to thank
Professor Peter Buhl Jensen for his years of dedicated work at TopoTarget,
which most recently led to an important partnership deal with Spectrum
Pharmaceuticals, Inc. regarding belinostat, and earlier the development and
market launch of Savene®/Totect® making a valuable treatment available for
cancer patients."

"I am extremely pleased to join TopoTarget. The Company has with its potential
best-in-class drug candidate, belinostat, an excellent platform for making a
difference in cancer treatment. On top of my agenda is to prepare the
commercialisation of belinostat together with Spectrum Pharmaceuticals in North
America, and in Europe, in Japan and in the emerging markets," said Dr.
Francois Martelet, new CEO of TopoTarget. "I look forward, together with the
dedicated team of TopoTarget, to maximising the value of this important asset
and to transform the Company into a leading European biotech company within
oncology."

"As one of the founders of TopoTarget, I am proud of having been part of
bringing the Company from an early-stage biotech company to an international
player in the field of cancer," said Professor Peter Buhl Jensen, former CEO of
TopoTarget. "Furthermore, I am proud that TopoTarget has been able to attract
Dr. Francois Martelet with his documented experience in the cancer area, as
well as being confident that Francois has the skills to bring belinostat
through late-stage development in order to make belinostat available for cancer
patients worldwide."

Dr. Francois Martelet has a solid late-stage development and commercialisation
experience from the international pharmaceutical industry, including Merck &
Co., Novartis, Schering-Plough, Eli Lilly and Roche. During his time with Merck
& Co. (2005-2007), he was Vice President & Worldwide Franchise Head, Oncology,
from which position he has gained in-depth knowledge of the HDACi drug class
via his role in the global launch of Zolinza®. More recently (2007-2009), he
was President & CEO of , AVAX Technologies, Inc., a US biotech company which is
specialised in cancer vaccines therapy. Francois Martelet is a bilingual
English/French speaker, and commands both German and Swedish. He holds a
doctorate with distinction in medicine and a masters degree in business (from
the Dijon University of Medicine, Dijon, France), and a degree in legal
medicine (Descartes University of Medicine, Paris, France). In addition, he has
attended advanced management development programs at both Harvard Business
School and INSEAD. Francois Martelet is a French national and 50 years old.

The change of responsibilities will take place with immediate effect. In order
to ensure a successful transition, Professor Peter Buhl Jensen will, on a
fulltime consultative basis, be available for TopoTarget for a six months
period in order to facilitate a satisfactory transfer of knowledge.

This announcement does not change TopoTarget's 2009 full-year financial
guidance.

TopoTarget A/S

For further information, please contact:

Håkan Åström
Chairman
Mobile: +46 703 747 213


Background information

About TopoTarget
TopoTarget (NASDAQ OMX: TOPO) is an international biotech company headquartered
in Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. TopoTarget currently focuses, in collaboration with Spectrum
Pharmaceuticals, Inc., on the development in pivotal studies of its lead drug
candidate, belinostat, which has shown proof of concept as monotherapy in
treating haematological malignancies and positive results in solid tumours.
Belinostat can be used in combination with full doses of chemotherapy, and is
in a pivotal trial within PTCL (peripheral T-cell lymphoma). TopoTarget's
expertise in translational research is based on utilising its highly predictive
in vivo and in vitro cancer models. TopoTarget is directing its efforts on key
cancer targets, including HDACi, NAD+, mTOR, FASLigand and topoisomerase II
inhibitors. The Company's first marketed product, Savene®/Totect®, was approved
by EMEA in 2006 and the FDA in 2007, and is marketed by TopoTarget's own sales
force in Europe and the US. For more information, please refer to
www.topotarget.com.

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialisation rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.

announcement no 05-10 topotarget announces new ceo to prepare commercialisation of belinostat.pdf